tbuckley/cabot-search huggingface dataset:
"CHRISTIAN SCIENCE" AND SLOPPY THINKING
Journal: JAMA (1920)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Announcement
Authors: Jambur Ananth, Randy Swartz, Karl Burgoyne, Rangaswamy Gadasally, P. Jess, P. Bech, Massimo Biondi, Margherita Peronti, Francesca Pacitti, Paolo Pancheri, Roberta Pacifici, Ilaria Altieri, Luciana Paris, Piergiorgio Zuccaro, Vanja Blomkvist, Tores Theorell, Hans Jonsson, Sam Schulman, Erik Berntorp, Lennart Stiegendal, Tim A. Ahles, Peter M. Silberfarb, Amy Chen Rundle, Jimmie C. Holland, Alice B. Kornblith, George P. Canellos, Mark R. Green, Michael C. Perry, Giovanni A. Fava, Murray A. Morphy, Nicoletta Sonino, Maurizio Fava, Evan Bouffides, Joel A. Pava, Mary K. McCarthy, Ronald J. Steingard, Jerrold F. Rosenbaum, Paul M. Copeland, Takehiko Ohzeki, Hiroshi Tachikawa, Kaname Tanimoto, Keiichi Hanaki, Hiroko Motozumi, Hiroko Ohtahara, Hirofumi Urashima, Toshinori Tsukuda, Kazuo Shiraki, Susan G. Ball, Michael W. Otto, Ernest H. Friedman
Journal: Psychotherapy and Psychosomatics (1994)
"CHRISTIAN SCIENCE" AND LEGAL CONSENTING CAPACITY.
Journal: JAMA (1901)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Reduced Relationship to Cortical White Matter Volume Revealed by Tractography-Based Segmentation of the Corpus Callosum in Young Children With Developmental Delay
Authors: Carissa Cascio
Journal: American Journal of Psychiatry (2006)

Objective: The corpus callosum is the primary anatomical substrate for interhemispheric communication, which is important for a range of adaptive and cognitive behaviors in early development. Previous studies that have measured the corpus callosum in developmental populations have been limited by the use of rather arbitrary methods of subdividing the corpus callosum. The purpose of this study was to measure the corpus callosum in a clinical group of developmentally delayed children using a subdivision that more accurately reflected the anatomical properties of the corpus callosum. Method: The authors applied tractography to subdivide the corpus callosum into regions corresponding to the cortical regions to and from which its fibers travel in a clinical group of very young children with developmental delay, a precursor to general mental retardation, in comparison with typically developing children. Results: The data demonstrate that the midsagittal area of the entire corpus callosum is reduced in children presenting with developmental delay, reflected in the smaller area of each of the fiber-based callosal subdivisions. In addition, while the area of each subdivision was strongly and significantly correlated with the corresponding cortical white matter volume in comparison subjects, this correlation was prominently absent in the developmentally delayed group. Conclusions: A fiber-based subdivision successfully separates lobar regions of the corpus callosum, and the areas of these regions distinguish a developmentally delayed clinical group from the comparison group. This distinction was evident both in the area measurements themselves and in their correlation to the white matter volumes of the corresponding cortical lobes.
The Stamp Tax and Proprietary Preparations.
Journal: JAMA (1898)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Therapeutics.
Authors: None Breninger
Journal: JAMA (1900)

Treatment of Diarrhea.J. T. Moore, in Merck's Archives for February, says that in the majority of diarrheas, a process of fermentation is to be found which has had its beginning in indigestion from im¬ proper food or improper feeding, the temperature being much aggravated by environments, particularly temperature range.These cases, if not given early attention, frequently pass into an inflammatory condition.But it is the diarrheas of
Missing Subtitle
Authors: John Tackett, Lisa Walke, Linda Accordino, Emily Melin, Troy Bishop, Chandrika Kumar, Ronnie Rosenthal, Rosenthal Tackett, Melin Tackett
Journal: JAMA Surgery (2014)

Daniel A. Anaya, MD; Jason Johanning, MD; Seth A. Spector, MD; Mark R. Katlic, MD; Albert C. Perrino, MD; Jessica Feinleib, MD, PhD; Ronnie A. Rosenthal, MD, MS
Peripheral neuropathy following tetanus toxoid administration
Authors: G. I. Blumstein
Journal: JAMA (1966)

THE INCIDENCE of anaphylaxis to horse serum administration is estimated to be one in 50,000 and that of serum sickness one in 20.<sup>1</sup>This significant risk has served to emphasize the superiority of active immunization against tetanus with toxoid over passive immunization with heterologous antitoxin. Significant local and systemic reactions to tetanus toxoid were not uncommon with the cruder preparations of yesteryear but have become less frequent with those currently available. In 1940, Cooke<sup>2</sup>reported cases of urticaria following booster injections of tetanus toxoid. This was shown to be due to the Berna peptone used in the culture media. A review of reactions to tetanus toxoid by Whittingham in 1940<sup>3</sup>indicated that acute anaphylactic reactions occurred in two of 61,000 inoculations or 0.003%. The incidence of constitutional and significant local reactions in the same series was 1%. The sensitizing agent in most of these cases was considered
Abstract 4465: The effect of insurance status on childhood and adolescent cancer survival using data from the National Cancer Database
Authors: Xiaoyan Wang, Rohit P. Ojha, Kimberly J. Johnson
Journal: Cancer Research (2019)

Abstract Background Differences in access, delivery or utilization of health care may impact childhood and adolescent cancer survival. In this study, we evaluated the impact of insurance coverage on survival among children and adolescents diagnosed with cancer, and explored potential mechanisms. Methods We obtained data from 58,421 individuals diagnosed with any cancer type at ≤ 19 years old from 2004-2010 from the National Cancer Database. We examined associations between insurance status at diagnosis or initial treatment and stage at diagnosis, treatment received (any vs. none), and all-cause mortality using logistic regression, Cox proportional hazards regression, restricted mean survival time and mediation analyses for all cancers combined and by cancer type. We evaluated the moderation effect of age on cancer death in association with insurance status using the likelihood-ratio test. Results Children and adolescents with Medicaid, unknown insurance, and those who were uninsured were more likely to be non-White, from lower income counties, be diagnosed at an advanced stage, and less likely to receive any treatment than those with private insurance. Those with Medicaid, unknown insurance, and who were uninsured had a 27% (95%CI, 1.22 to 1.33), 39% (95%CI, 1.26 to 1.53), and 32% (95%CI, 1.20 to 1.46) higher hazard of death during 5 years of follow-up versus those with private insurance. Survival at 60 months was modestly lower for these groups than those who were privately insured at 1.73 months (95%CI, -2.07 to -1.38), 2.48 months (95%CI, -3.29 to -1.68), and 2.13 months (95%CI, -2.91 to -1.34). The higher mortality risk and lower survival months in non-privately insured cases were observed for most cancer types. In mediation analyses, for Medicaid and uninsured patients, earlier diagnosis for staged cancers was estimated to reduce the survival deficit by approximately one fourth and one half. Treatment did not account for the insurance associated survival difference. Conclusion Enhancing existing insurance coverage and ensuring equal and early diagnosis may help to improve survival overall for children and adolescents diagnosed with cancer. Future qualitative studies are needed to understand institutional and family level barriers to diagnosis and care of children with cancer and to further explain the underlying mechanisms for differences in childhood survival by insurance status. Citation Format: Xiaoyan Wang, Rohit P. Ojha, Kimberly J. Johnson. The effect of insurance status on childhood and adolescent cancer survival using data from the National Cancer Database [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 4465.
Book Review A Textbook of Dietetics . By L. S. P. Davidson. B.A. (Cantab.), M.D. (Edin.), F.R.C.P. (Edin. and Lond.), F.R.S.E. and Ian A. Anderson, M.B., Ch.B. (Aberd.). With diet sheets constructed by Miss Mary E. Thomson, S.R.N., and a foreword by Sir John Boyd Orr, M.D., D.Sc., LL.D., F.R.S. 8°, cloth, 324 pp., with 27 tables. New York: Paul B. Hoeber, Incorporated, 1941. $4.25.
Journal: New England Journal of Medicine (1942)
Recombinant human interferon α‐2b (rh IFNα‐2b) therapy for steroid resistant idiopathic thrombocytopenic purpura (ITP)
Authors: Kingo Fujimura, Toshiro Takafuta, Shin‐ichiro Kuriya, Tsukasa Abe, Jun‐ichi Akatsuka, Kojiro Yasunaga, Tatsumi Uchida, Makoto Kawakita, Kiyoshi Kitamura, Takeo Nomura, Atsushi Kuramoto
Journal: American Journal of Hematology (1996)

The efficacy of recombinant human interferon α-2b (rh IFNα-2b) in the treatment of steroid resistant idiopathic thrombocytopenic purpura (ITP) was studied in 50 cases. Forty-one patients treated with rh IFNα-2b three times a week, six of 18 (33.3%) in the low dose group (150 × 104IU: 3 MIU) and four of 20 (20.0%) in the high dose group (300 × 1010IU: 3 MIU) responded with platelet counts increasing to above 50 × 109/L. Because of the exacerbation of thrombocytopenia and nasal bleeding, treatment was discontinued within 2 weeks in three patients out of 41 cases. On the other hand, six of nine patients (66.7%) treated with 3 MIU of IFNα-2b once a week for 8 weeks showed satisfactory response. Treatment with either administration schedule did not result in sustaining platelet counts above 50 × 109/L for a long time after treatment. The results indicate that once a week administration schedule of rh IFNα-2b is more efficacious for platelet counts increasing for short period in patients who failed to respond to steroid and other medications than other schedules. The maintenance of this treatment schedule will allow sustained increased platelet levels, resulting in relief of bleeding tendency, while also being cost effective in comparison with other IFN treatment schedules and achieving better patient compliance without flu-like symptoms. © 1996 Wiley-Liss, Inc.
FAK-PD1: a phase I/IIa trial of FAK (defactinib) &amp; PD-1 (pembrolizumab) inhibition
Authors: S. Symeonides, T.R.J. Evans, V. Coyle, A. Serrels, F. Thomson, D. Currie, S. Dillon, J. Paul, D.A. Fennell, C. Ottensmeier
Journal: Annals of Oncology (2017)
Guideline change for antiviral therapy reduced the risk of HBV-related HCC development among cirrhotic patients in South Korea
Authors: David Kim, Jae Seung Lee, Ho Soo Chun, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Kwang-Hyub Han, Yu Rim Lee, Won Young Tak, Young Oh Kweon, Sang Hoon Ahn, Seung Up Kim
Journal: Journal of Hepatology (2020)
Human Exposures to Volatile Halogenated Organic Chemicals in Indoor and Outdoor Air
Authors: Julian B. Andelman
Journal: Environmental Health Perspectives (1985)

Volatile halogenated organic chemicals are found in indoor and outdoor air, often at concentrations substantially above those in remote, unpopulated areas. The outdoor ambient concentrations vary considerably among sampling stations throughout the United States, as well as diurnally and daily. The vapor pressures and air-water equilibrium (Henry's Law) constants of these chemicals influence considerably the likely relative human exposures for the air and water routes. Volatilization of chemicals from indoor uses of water can be a substantial source of exposure, as shown for radon-222. Measurements of air concentrations of trichloroethylene (TCE) in showers using TCE contaminated groundwater show increases with time to as high as one-third of occupational threshold limit values. Using a scaled down experimental shower, such volatilization and subsequent decay in air was also demonstrated. Using a simplified indoor air model and assuming complete volatilization from a full range of typical water uses within the home, calculations indicate that the expected air inhalation exposures can be substantially higher than those from ingestion of these chemicals in drinking water. Although the regulation of toxic chemicals in potable water supplies has focused traditionally on direct ingestion, the volatilization and inhalation from other much greater volume indoor uses of water should be considered as well.
Alopecia.
Authors: John K. Morgan
Journal: British Journal of Dermatology (1966)

Journal Article Alopecia. Get access John K. Morgan John K. Morgan Carter Bequest Hospital, Middlesbrough, Yorks Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 78, Issue 6, 1 June 1966, Page 364, https://doi.org/10.1111/j.1365-2133.1966.tb14695.x Published: 01 June 1966
Acyclovir therapy for herpes zoster: advantages and adverse effects
Authors: H. H. Balfour
Journal: JAMA (1986)

Acyclovir sodium administered intravenously to treat acute herpes zoster in an immunocompromised patient was associated with side effects as described by Sylvester et al in this issue ofThe Journal.<sup>1</sup>The CASE REPORT raises several important questions: Should acyclovir be used for treatment of herpes zoster, and, if so, what dosage is appropriate and what adverse effects can be expected? Acyclovir is a specific inhibitor of the DNA polymerase of all five members of the human herpesvirus family and thus the drug is potentially useful for treatment of many herpes-virus-associated diseases. The median sensitivity of herpes simplex virus (HSV) type 2 strains to acyclovir as measured by plaque reduction is 0.4μM.<sup>2</sup>Plasma concentrations fivefold higher than this can be attained by ingesting one 200-mg acyclovir capsule. Therefore, it is not surprising that acyclovir is the drug of choice for treatment of primary<sup>3</sup>and recurrent<sup>4</sup>genital herpes, herpes
Retrospective study of clinical and radiographic risk factors associated with early onset, severe pulmonary hemorrhage in bevacizumab-treated patients with advanced non-small cell lung cancer (NSCLC)
Authors: A. B. Sandler, V. Hirsh, M. Reck, V. Archer, M. K. Samant, L. Wang, D. K. Strickland, I. Dimery, D. H. Johnson
Journal: Journal of Clinical Oncology (2008)

8074 Background: Bevacizumab (Bv) with carboplatin/paclitaxel prolongs survival in non-squamous NSCLC, but is associated with fatal pulmonary hemorrhage (PH) in E4599. A retrospective study was conducted using data from studies E4599 and the phase II study AVF0757g to potentially identify clinical or radiographic (CT) risk factors associated with early onset (< 150 days from initial treatment) PH, although the small number of events limited the ability to fully assess the risk factors (Sandler, ASCO 2006, abstract 7068). We provide updated results from those analyses pooling additional data from study AVAiL. Methods: A broad search of the database for selected bleeding terms among Bv-treated patients was conducted and cases of PH were identified. A case-control analysis was conducted for baseline CT variables using a subset of patients not identified as potential cases of PH that were randomly selected from Bv-treated patients and matched to cases based on gender, age group, histology (phase II only) and dose group (AVAiL only). All Bv-treated patients were included in the cohort analysis of baseline clinical factors. Chest CTs were evaluated by blinded independent assessment of lesion location, presence and size of cavitation, size of largest tumor or nodal mass, vascular or tracheobronchial involvement, and total number of intra-thoracic lesions. Results: From the pooled data, 21 cases of PH were identified among the 1142 Bv-treated patients. The cohort analysis of baseline clinical risk factors for these cases is presented (table 1). Conclusion: PH was an uncommon event, with an incidence of 1.8% among patients who received Bv in these 3 studies. There does not appear to be an association between baseline clinical variables and early-onset PH. The pooled case-control analysis for radiologic variables is ongoing and will be presented. Table 1. Cohort analysis of baseline clinical risk factors. Pooled (AVAIL + E4599 + AVF0757g) Baseline clinical factor Variable N PH Case (%) Sex Female Male 475 667 8 (1.7) 13 (1.9) Age <65 ≥65 758 384 13 (1.7) 8 (2.1) ECOG PS 0 1 467 673 5 (1.1) 16 (2.4) Prior surgery * No Yes 915 159 15 (1.6) 0 (0) Prior radiotherapy No Yes 1069 71 19 (1.8) 2 (2.8) * Data not collected in study AVF0757g. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Genentech™ BioOncology, Hoffman-La Roche Genentech™ BioOncology, Hoffman-La Roche, Idera, Merck Genentech™ BioOncology Bayer, Boehringer Ingelheim, Genentech™ BioOncology, Hoffman-La Roche, Lilly Oncology Genentech™ BioOncology
Depression in Women with Spontaneous 46, XX Primary Ovarian Insufficiency
Authors: Peter J. Schmidt, Jamie A. Luff, Nazli A. Haq, Vien H. Vanderhoof, Deloris E. Koziol, Karim A. Calis, David R. Rubinow, Lawrence M. Nelson
Journal: Endocrine Reviews (2010)

Context A high prevalence of depressive symptoms is observed in women with primary ovarian insufficiency (POI) compared with women in whom the menopause is normally timed. Indeed, studies suggest that depression and/or its pharmacological treatment contribute to the onset of POI. Objectives We characterize the prevalence of psychiatric disorders and the timing of onset of clinically significant depression relative to both the diagnosis of POI and the onset of menstrual irregularity in women with POI. Design and Setting We conducted a cross-sectional clinic-based study at the National Institutes of Health Clinical Research Center. Patients A total of 174 women with spontaneous 46, XX POI and 100 women with Turner syndrome participated in the study. Main Outcome Measures The structured clinical interview for DSM-IV was performed. Results Lifetime histories of depression in POI exceeded rates of depression reported in women with Turner syndrome and community-based samples of women (P &amp;lt; 0.001). The onset of depression frequently preceded the diagnosis of POI but occurred after the onset of menstrual irregularity. Analyses standardizing the periods of risk for depression showed that similar numbers of depressions occurred before and after these events. Conclusions POI is associated with an increased lifetime risk for major depression. Attention to the presence of depression in POI should become an important part of the care for these women. The onset of depression frequently occurs after signs of altered ovarian function but before the diagnosis of POI. Thus, in some women the association between POI and depression suggests an overlapping pathophysiology rather than a causal relationship.
The Heron
Authors: Tom Strouse
Journal: JAMA (1985)

With me, in the green rowboat, the pond misting itself into day behind him, my father taught me to play a fish; with wide soft hands over mine, he'd let them run, and wait, and set the hook. I've tried to remember his hands, to hold for that moment as the line pays out, where my heart empties itself into my wrists: they twitch, held off like two stunned grasshoppers then flick the bail over, tear the pole upwards in turn threading line and bloodknot and leader back through the water, sometimes setting the treble hooks deep but mostly missing. We fish together still, same boat, the voice and the hands beside me strong as ever, strong as the magnet of water where a bass sucks and spits at my bait with its white tongue. In the hush after a missed fish knowing the mistake, I say it out loud